Hikal announced it has received the Establishment Inspection Report
(EIR) from the US Food and Drug Administration (US FDA) for its API Unit located at Jigani, Bangalore for the inspection conducted in July 2019. The inspection resulted in one minor FDA Form 483 which was closed out immediately.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
